What we do
Our pipeline

Pipeline

We are actively advancing our pipeline - both late- and early-stage programs - built on our recombinant protein-based nanoparticle and proprietary Matrix-M™ adjuvant technology platform. We are focusing on high-value assets in areas with unmet medical need, compelling scientific rationale and strong commercial opportunity. We intend to develop our early-stage pipeline using a disciplined and capital-efficient approach. Our R&D investment strategy will allow us to place smart, lower-cost bets on the highest-value programs, both within infectious disease and beyond. 
 

Our pipeline

Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.

Our Matrix-M adjuvant technology

Matrix-M adjuvant

The vaccines listed below have been developed with the Matrix-M adjuvant.

Learn more about our technology platform
Vaccines in Novavax Pipeline and Status
Therapeutic area
Candidate
Phase of trial
Authorized Use
Partner
  
Preclinical
Phase 1
Phase 2
Phase 3
  
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine
    
 
Authorized1
Respiratory diseases
COVID-19 + seasonal influenza
COVID-influenza combination (CIC) vaccine
   
 
Phase 3
Novavax led
Respiratory diseases
Seasonal influenza
Influenza vaccine (Older Adults)
   
 
Phase 3
Novavax led
Respiratory diseases
Respiratory syncytial virus (RSV)
RSV Combinations (RSV, hMPV, other respiratory)
 
Preclinical
   
Novavax led
Respiratory diseases
H5N1 avian pandemic influenza
Highly pathogenic H5N1 avian pandemic influenza vaccine
 
Preclinical
   
Novavax led
Viral infection
Varicella-zoster (shingles)
Shingles vaccine
 
Preclinical
   
Novavax led
Bacterial disease
Clostridioides difficile (C. diff) colitis
C. diff vaccine
 
Preclinical
   
Novavax led
Developed by partners leveraging Novavax technology
Parasitic diseases
Malaria
R21/Matrix-MTM adjuvant
    
 
Authorized2
Respiratory diseases
COVID-19 + seasonal influenza
TIV-HD (FLUZONE High-Dose) - NCT06695117
  
 
Phase 1/23
 
Respiratory diseases
COVID-19 + seasonal influenza
RIV3 (FLUBLOK) - NCT06695130
  
 
Phase 1/23
 
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine
 
Authorized1
Partner
Respiratory diseases
COVID-19 + seasonal influenza
COVID-influenza combination (CIC) vaccine
 
Phase 3
Partner
Novavax led
Respiratory diseases
Seasonal influenza
Influenza vaccine (Older Adults)
 
Phase 3
Partner
Novavax led
Respiratory diseases
Respiratory syncytial virus (RSV)
RSV Combinations (RSV, hMPV, other respiratory)
 
Preclinical
Partner
Novavax led
Respiratory diseases
H5N1 avian pandemic influenza
Highly pathogenic H5N1 avian pandemic influenza vaccine
 
Preclinical
Partner
Novavax led
Viral infection
Varicella-zoster (shingles)
Shingles vaccine
 
Preclinical
Partner
Novavax led
Bacterial disease
Clostridioides difficile (C. diff) colitis
C. diff vaccine
 
Preclinical
Partner
Novavax led
Developed by partners leveraging Novavax technology
Parasitic diseases
Malaria
R21/Matrix-MTM adjuvant
 
Authorized2
Partner
Respiratory diseases
COVID-19 + seasonal influenza
TIV-HD (FLUZONE High-Dose) - NCT06695117
 
Phase 1/23
Partner
Respiratory diseases
COVID-19 + seasonal influenza
RIV3 (FLUBLOK) - NCT06695130
 
Phase 1/23
Partner

1 Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax™; and Nuvaxovid™. Authorization information can be found by country at https://novavaxcovidvaccine.com.


2 Commercialized by Serum Institute of India and granted prequalification by the WHO and distributed by UNICEF to endemic countries in Africa.


3 Granted Fast Track designation in the US

What we do

Driving value through targeted innovation with our validated technology

Learn about our technology

Who we are

Novavax is powered by global collaborations

Learn about our partners